CABA Stock Summary and Trading Ideas (Cabaletta Bio | NASDAQ:CABA)

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.

As of May 6, 2024, CABA stock price climbed to $12.86 with 311,254 million shares trading.

CABA has a beta of 2.78, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.15 to the broad based SPY ETF.

CABA has a market cap of $620.39 million. This is considered a Small Cap stock.

In the last 3 years, CABA stock traded as high as $26.35 and as low as $.59.

The top ETF exchange traded funds that CABA belongs to (by Net Assets): XBI, VTI, IWM, VXF, LABU.

CABA has underperformed the market in the last year with a price return of +5.1% while the SPY ETF gained +27.7%. CABA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.6% and -3.6%, respectively, while the SPY returned +4.4% and +3.9%, respectively.

CABA support price is $11.67 and resistance is $13.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA stock will trade within this expected range on the day.